RKDA

Arcadia Biosciences, Inc. (RKDA) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.5/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.8 (Weak)

RKDA lacks disclosed 5-year revenue, EPS, and FCF CAGR data, limiting evidence of repeatable compounding versus peers with demonstrated multi-year growth.

Negative TTM ROIC of -95.6% indicates current capital deployment is destroying value, which weakens reinvestment-led revenue expansion relative to profitable peers.

Zero capex and R&D intensity suggest limited internal growth investment, reducing the company’s ability to build scalable product or operational expansion versus peers.

Negative EV-to-sales and negative FCF yield imply the market is pricing in weak monetization and poor cash generation, both of which constrain growth reinvestment capacity.

Market Tailwinds

Score:

No segment concentration or share data is provided, so there is no evidence of a dominant end-market position that could support durable multi-year expansion versus peers.

The absence of disclosed growth history makes it difficult to verify that RKDA benefits from persistent demand tailwinds rather than episodic revenue swings.

Compared with peers that show measurable CAGR and operating leverage, RKDA’s available metrics do not demonstrate a market structure capable of compounding revenue at scale.

Negative profitability metrics suggest any demand gains have not yet translated into durable commercial traction, limiting confidence in long-term tailwind capture.

Scalability Expansion

Score:

Negative ROIC and missing margin history indicate the business has not yet proven scalable economics, unlike peers that convert growth into improving returns.

The lack of R&D and capex intensity implies limited reinvestment capacity, which constrains the company’s ability to expand capacity or broaden offerings over time.

A negative cash conversion cycle is operationally helpful, but it is not enough to offset the absence of evidence for scalable revenue compounding versus peers.

With no disclosed 5-year growth metrics, RKDA’s expansion profile remains unproven, while stronger peers can point to repeatable scaling across cycles.

Constraints Limitations

Score:

The most binding constraint is the absence of demonstrated multi-year growth, which limits confidence that RKDA can compound revenue sustainably versus peers.

Severely negative ROIC signals that additional capital has not translated into durable expansion, creating a structural hurdle to efficient scaling.

Minimal disclosed investment in R&D and capex suggests a narrow internal growth engine, which can cap long-term revenue expansion if external funding remains limited.

Compared with peers that show positive returns and visible reinvestment pathways, RKDA appears more constrained by execution and monetization than by market opportunity.

Overall Score

Score:

RKDA’s long-term growth capacity appears structurally constrained because the available metrics show no proven multi-year compounding, deeply negative ROIC, and limited reinvestment evidence versus peers.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Arcadia Biosciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →